Kornimate/medical-research-clean huggingface dataset:
effects of remote ischemic conditioning on myocardial perfusion in humans

Conditions: Ischemic Heart Disease

Summary: cardiovascular disease is the second leading cause of death in denmark, and ischemic heart disease accounts for the bulk of it. the purpose of this study is to clarify whether a mechanical method of remote ischemic conditioning in the form of short-term obstruction of the blood supply to the arm, can improve the heart's blood supply in patients with ischemic heart disease. this will be attempted through experiments on patients with ischemic heart disease and experimental animal studies with simulated cardiovascular disease. this study will help to clarify whether remote ischemic preconditioning can be used to treat patients with ischemic heart disease.


Eligibility criteria:
inclusion criteria: * patients referred for routine myocardial rb82-pet scanning at dept. of nuclear medicine \& pet center, aarhus university hospital, skejby, denmark. * able to understand the written patient information and to give informed consent. exclusion criteria: * patients not undergoing rb82-pet with adenosine stress test. * strenuous exercise (running, bicycling, fitness), intake of beta-blockers or alcohol intake on the day before and on the day of investigation. * pregnant/nursing women. * fertile women not using contraceptives. * patients in dialysis treatment. * other concomitant disease or treatment that according to the investigator's assessment makes the patient unsuitable for study participation. * known type 2 diabetes

Keywords: remote ischemic conditioning ischemic heart disease
effect of atropine or glycopyrrolate on the prevention of bradycardia during sedation using dexmedetomidine in geriatric patients undergoing total knee replacement under spinal anesthesia

Conditions: Spinal Anesthesia

Summary: patients undergoing total knee arthroplasty with spinal anesthesia are often sedated to reduce patient discomfort due to large noises during surgery and also to reduce anxiety. most commonly used sedatives include propofol and midazolam, but these agents often cause hypotension or respiratory depression, especially in elderly patients. dexmedetomidine is a selective alpha 2 adrenergic drug, which acts as a sedative and also has analgesia effects. in contrast to propofol or midazolam, dexmedetomidine rarely causes respiratory depression, and therefore is often used in critically ill patients in the icu and also in patients undergoing simple procedures. hemodynamically, dexmedetomidine evokes a biphasic blood pressure response with a short hypertensive phase and subsequent hypotension. bradycardia is also observed in many patients, which may lead to more serious outcomes in elderly patients who often have multiple comorbidities. therefore, drugs to prevent bradycardia during dexmedetomidine infusion may help patients maintain a more stable hemodynamic state. the present study aims to compare the ability of atropine and glycopyrrolate to prevent bradycardia during dexmedetomidine infusion in elderly patients undergoing knee surgery with spinal anesthesia.


Eligibility criteria:
inclusion criteria: 1. patients 65 years or older undergoing total knee replacement surgery under spinal anesthesia. 2. asa class 1-3 exclusion criteria: 1. patients with coagulation abnormalities 2. end organ diseases of liver, lung or kidney 3. severe aortic stenosis 4. high degree av block 5. heart failure 6. patients on mao inhibitors 7. history of seizures or epilepsy 8. glaucoma

Keywords: atropine glycopyrrolate bradycardia dexmedetomidine spinal anesthesia
clinical study for al-cm

Conditions: Immunoglobulin Light Amyloidosis Cardiomyopathy

Summary: in this study, patients diagnosed with al-cm were selected to observe the effect of treatment and conduct long-term follow-up.


Eligibility criteria:
inclusion criteria: * patients aged 18-90 years, regardless of gender, diagnosed with al-cm at the second affiliated hospital of zhejiang university school of medicine; * patients have the ability to understand the test, can cooperate with investigators. exclusion criteria: * unable to understand or unwilling to fill in informed consent forms or follow visitors
neuroprotective/neurotrophic effect of lexapro® in patients with posttraumatic stress disorder

Conditions: Posttraumatic Stress Disorder

Summary: the objectives of the current study are 1. to evaluate the efficacy of escitalopram in treatment for post-traumatic stress disorder, 2. to find the structural changes of brain using magnetic resonance imaging and its association with the symptoms reduction, and 3. to look at the differences of brain imaging findings and symptoms changes according to genetic differences of brain-derived neurotrophic factor (a biological molecule facilitating neuronal growth in human).


Eligibility criteria:
inclusion criteria: * 18-65 year-old male or female * ptsd diagnosed by scid-iv exclusion criteria: * previous or current treatment history for ptsd * neurologic disease (eg., epilepsy, infarct, multiple sclerosis, brain tumor) * any other axis i psychiatric disorder diagnosed by scid-iv * borderline personality disorder or antisocial personality disorder * iq below 80 * any contraindication to mri scan * any current psychotropic medication * unstable medical illness or severe abnormality in laboratory test at screening assessment * women who are pregnant, breastfeeding, or planning pregnancy * any contraindications to drug used in the study (e.g., allergy, intolerance, etc.)

Keywords: posttraumatic stress disorder escitalopram magnetic resonance imaging bdnf
real-time ultrasound guidance for thoracic epidural blocks

Conditions: Analgesia; Thoracic Tumors; Abdomen Tumors; Rib Fractures

Summary: various modalities have been proposed for real-time confirmation of loss of resistance (lor) for thoracic epidural blocks. with real-time ultrasound (us) guidance, the anesthesiologist attempts to visualize the sonographic advancement of the epidural needle and penetration of the epidural space (as detected by lor) this observational study is set out to confirm the reliability of real-time ultrasound guidance as an adjunct to lor for thoracic epidural blocks.


Eligibility criteria:
inclusion criteria: * age between 18 and 80 years * american society of anesthesiologists classification 1-3 * body mass index between 20 and 35 (kg/m2) exclusion criteria: * adults who are unable to give their own consent * sepsis (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. leukocytosis, increased c-reactive protein, increased procalcitonin) * coagulopathy (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. platelets ≤ 100, international normalized ratio ≥ 1.4 or prothrombin time ≥ 50) * allergy to local anesthetics (las) * prior surgery in the thoracic spine

Keywords: thoracic peridural ultrasound-guided
evaluation of ocoxin-viusid® in advanced pancreatic adenocarcinoma

Conditions: Adenocarcinoma of the Pancreas; Pancreatic Cancer; Advanced Cancer; Digestive System Neoplasms; Pancreatic Neoplasms; Endocrine Gland Neoplasms; Digestive System Diseases; Endocrine System Diseases; Pancreatic Diseases

Summary: the investigators hypothesized that with the administration of the nutritional supplement ocoxin-viusid® is expected to improve the quality of life and enhance tolerance to chemotherapy in at least 70% of patients diagnosed with advanced pancreatic adenocarcinoma, treated at the "hermanos ameijeiras" surgical clinical hospital. phase ii clinical trial, open, multicenter, nonrandomized.

to assess the effect of ocoxin-viusid® on the quality of life of patients with advanced pancreatic adenocarcinoma. to evaluate the effect of ocoxin-viusid® on the quality of life of patients. to evaluate the influence of ocoxin-viusid® on tolerance to onco-specific therapy. identify the changes that occur in the nutritional status of patients receiving the supplement. to evaluate the toxicity of ocoxin-viusid® in combination with chemotherapy in patients with advanced pancreatic adenocarcinoma.

Eligibility criteria:
inclusion criteria: * patients of any sex, resident in cuba, with an age greater than or equal to 18 years. * patients that meet the diagnostic criteria. * patients with general health according to karnofsky ≥70 %. * life expectancy greater than or equal to 3 months. * patients eligible to receive chemotherapy. * patients who have signed the informed consent. * patients who have laboratory values in parameters that do not contraindicate the administration of chemotherapy: * hemoglobin ≥ 90 g / l. * total leukocyte count ≥ 3.0 x 109 / l. * absolute neutrophil count ≥1.5 x 109 / l. * platelet count ≥100 x 109 / l. * total bilirubin values ≤ 1.5 times the upper limit of the normal range established in the institution. * tgo and tgp values ≤2.5 times the upper limit of the normal interval established in the institution. * creatinine values within the normal limits of the institution. exclusion criteria: * pregnant or lactating patients. * patients with known hypersensitivity to any of the active ingredients of the chemotherapy used * patients who are receiving another product under investigation. * patients with decompensated intercurrent diseases, including: hypertension, diabetes mellitus, ischemic heart disease, active infections, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, liver damage or any other special condition that at the discretion of the doctor puts their health at risk and his life during the study or his participation in the trial. * patients with brain metastases. * patients with mental disorders that may limit adherence to the requirements of the clinical trial and may hinder the collection of information, treatment or follow-up. it is planned to include a total of 30 patients in the study, taking into account 10% of losses.

Keywords: nutritional supplement advanced pancreatic adenocarcinoma ocoxin-viusid oxidative stress antioxidant
comparison of atomoxetine and placebo in children and adolescents with adhd and odd

Conditions: Attention Deficit Hyperactivity Disorder; Oppositional Defiant Disorder

Summary: the purpose of this trial is to test the effectiveness of atomoxetine in treating symptoms of odd in children with adhd and odd.


Eligibility criteria:
inclusion criteria: * patients are male or female outpatients who are at least 6 years of age and not more than 12 years of age at study entry. * patients must meet dsm-iv diagnostic criteria for adhd and odd. * if other comorbid conditions are present, either the adhd or the odd diagnosis must be the patient's primary diagnosis. * patients must have laboratory results, including serum chemistries, hematology, and urinalysis showing no significant abnormalities. * patients must have an ecg performed at study entry that is absent of any abnormality that, in the opinion of the physician, should exclude the patient. exclusion criteria: * patients who weigh less than 20 kg or greater than 60 kg at study entry. * patients who have a history of bipolar i or ii disorder, psychosis, or pervasive developmental disorder. * patients who have a current diagnosis of major depressive disorder (\[mdd\]; with or without psychotic features), ptsd, or cdrs-r total raw score \>40 at study entry. * patients with a history of any seizure disorder. * patients determined by the investigator to be at serious suicidal risk.
weekly vs daily teriparatide therapy in severe postmenopausal osteoporosis

Conditions: Osteoporosis

Summary: osteoporosis is characterized by decreased bone strength and it is prevalent among postmenopausal women but also occurs in men and women with underlying conditions or major risk factors associated with bone demineralization. its chief clinical manifestations are vertebral and hip fractures, although fractures can occur at any skeletal site.the world health organization (who) operationally defines osteoporosis as a bone density that falls 2.5 standard deviations (sd) below the mean for young healthy adults of the same gender-also referred to as t-score of -2.5. postmenopausal women who fall at the lower end of the young normal range (a t-score of \>1 sd below the mean) are defined as having low bone density (osteopenia) and are also at increased risk of osteoporosis. more than 50% of the fractures, including hip fractures, among postmenopausal women occur in this group. teriparatide is one of the most effective treatment options for osteoporosis. but the cost of teriparatide is prohibitively expensive and in countries like india with limited personal resources of the individuals, its not a feasible option in the majority of the patients with severe osteoporosis. the investigators aim to compare weekly versus daily teriparatide therapy in an open label non inferiority trial and if successful, the investigators anticipate, the cost of treatment could be reduced considerably so that treatment becomes more affordable to a larger number of patients. also with weekly therapy, number of multiple injections could be brought down.


Eligibility criteria:
inclusion criteria: * postmenopausal women of age group 50-70 having t score less than -2.5 sd or lower at lumbar spine or proximal femur. exclusion criteria: * patients with renal dysfunction (serum creatinine \>1.5) * primary and secondary hyperparathyroidism * secondary osteoporosis * unexplained elevated alp (alkaline phosphatase) * history of therapeutic radiation * active malignancy and patients having implant * patients who have received i.v. or oral bisphosphonates in their disease course

Keywords: osteoporosis teriparatide
use of extended release triamcinolone in the treatment of rotator cuff disease

Conditions: Rotator Cuff Tears; Rotator Cuff Tendinitis; Rotator Cuff Impingement; Injections; Glucocorticoids

Summary: the primary objective of this study is to assess the overall safety and general tolerability of extended release triamcinolone acetate (ta-er/fx006) in patient with rotator cuff disease. the study will enroll 65 patients, aged 40-75 years old, in a longitudinal case series level iv study using extended release triamcinolone to treat shoulder pain from rotator cuff disease. inclusion criteria will be shoulder pain without a history of trauma and physical exam consistent with rotator cuff tendinitis, impingement syndrome or rotator cuff tear.

the purpose of this study is to assess the safety and efficacy of ta-er in the treatment of rotator cuff disease. the study will enroll 65 patients in a longitudinal case series level iv study using extended release triamcinolone to treat shoulder pain from rotator cuff disease. inclusion criteria will be shoulder pain without a history of trauma and physical exam consistent with rotator cuff tendinitis, impingement syndrome or rotator cuff tear. patients will have normal xrays or xrays indicative of chronic cuff tearing and a musculoskeletal ultrasound indicating an intact rotator cuff, partial cuff tearing or cuff tear. patients will undergo an ultrasound guided injection of ta-er into the subacromial space from a lateral access point at the time of the examination. they will be monitored for any immediate adverse effects. patient reported outcomes measures will be recorded with online questionnaires which include a visual analog scale (vas), single assessment numeric evaluation (sane), veteran's rand 12 (vr-12) and american shoulder and elbow scale (ases) and will be recorder pre-treatment and at 2, 4, 8 and 12 and 24 weeks post treatment. patients will be asked to follow up for an in person evaluation at 4 weeks, 12 weeks and 24 weeks post injection.

Eligibility criteria:
inclusion criteria: 1. male or female between the ages of 40-75 years old. 2. able and willing to give written informed consent in accordance with the irb. 3. read and speak english. 4. history indicative of rotator cuff disease. 5. physical exam consistent with rotator cuff disease. 6. all patients will have ap and outlet x ray views. 7. x rays will be normal or indicative of chronic rtc tearing 8. musculoskeletal ultrasound indicating intact rtc, full thickness tears, or large and massive cuff tears in older, sedentary individuals. 9. willing to abstain from use of nsaids exclusion criteria: 1. females who are pregnant or nursing or plan to become pregnant during the study; men who plan to conceive during the study; or unwilling to practice birth control during participation in the study. 2. presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data. 3. known or suspected hypersensitivity to fx006 (or component of fx006), triamcinolone acetonide.
be-healthy: behavioral risk factors for poor vascular health in youth

Conditions: Prehypertension; Hypertension; Overweight and Obesity; Elevated Blood Pressure; Endothelial Dysfunction; Vascular Stiffness; Sleep

Summary: the investigators aim to determine the association of dietary intake on cardiovascular disease risk factors among children with overweight and obesity who are being evaluated for elevated blood pressure. the investigators will also investigate for predictors of vascular function and determine if predictors vary by level of sodium intake.

this research is being done to determine if the food or salt eaten can cause arteries to be stiffer and/or not work as well and if it can impact blood pressure over a 24-hour period of time. the investigators also want to determine if there are any risk factors or blood tests that can predict how stiff arteries are or how well arteries function. the investigators hope that the information from this study will help the investigators prevent blood pressure-related cardiovascular disease in children. this knowledge could help shape future guidelines on how to best prevent and treat high blood pressure and heart disease in children.

Eligibility criteria:
inclusion criteria: * overweight or obese * elevated blood pressure * referred to the renew clinic at johns hopkins university for evaluation and treatment of elevated blood pressure. exclusion criteria: * the only children who will not be eligible for inclusion in this study are those who are non-english speaking.
high-frequency scs in treatment of chronic limb-threatening ischemia

Conditions: Chronic Limb-Threatening Ischemia

Summary: the study of high-frequency spinal cord stimulation (scs) efficacy in the treatment of chronic limb-threatening ischemia (clti)

open-label, parallel-group, randomized study with a 1:1 allocation ratio to check the hypothesis of whether high-frequency-scs (hf-scs) is better than conventional low-frequency (lf-scs) for pain relief in patients with chronic limb-threatening ischemia (clti).

Eligibility criteria:
inclusion criteria: * non-reconstructable critical limb-threatening ischemia (clti) * fontaine stage iib-iv * vas score 5/10 or more * succesful scs trial exclusion criteria: * intractable acute infection * allergy to scs component * ulcerations larger than 3 cm2 * inadequate patient compliance * life expectancy less than 12 months * patient refuse to participate in any stage of the study
tailored bilio-pancreatic limb and hba1c 10 years post mini-gastric bypass

Conditions: Diabetes; Surgery

Summary: diabetes is now or soon will be a worldwide epidemic. diabetes has impact on both healthcare costs in addition to the costs in human lives, suffering and disability. treatment that lowers hemoglobin a1c (hba1c) improved outcomes. studies have demonstrated that both general surgery and bariatric procedures may improve or reverse diabetes. in several studies the billroth ii reconstruction following gastrectomy was the most effective surgical technique in improving or reversing diabetes. the purpose of this study is to analyze the outcomes of the mini-gastric bypass-original technique (mgb-ot) version of the one anastomosis bypass (oagb) to investigate the association of a "tailored" bilio-pancreatic limb length (bpll) with the hba1c changes.

there is general agreement that diabetes is now or soon will be a worldwide epidemic. studies also make clear the devastating impact of diabetes on both healthcare costs in addition to the costs in human lives, suffering and disability. it is also clear that treatment that lowers hemoglobin a1c (hba1c) will result in improved outcomes proportional to the decrease, saving both lives and costs. unfortunately medical and lifestyle therapy routinely result in less than ideal resolution of elevated hba1c levels. studies have demonstrated that both general surgery and bariatric procedures may improve or reverse diabetes. in several studies the billroth ii reconstruction following gastrectomy is the most effective surgical technique in improving or reversing diabetes. the purpose of this study is to analyze the outcomes of the mini-gastric bypass-original technique (mgb-ot) version of the one anastomosis bypass (oagb) to investigate the association of a "tailored" bilio-pancreatic limb length (bpll) with the hba1c changes.

Eligibility criteria:
inclusion criteria: * mini-gastric bypass -original technique post operative patients exclusion criteria: -